ORBITO

Oral biopharmaceutics tools
logo orbito

FACTS & FIGURES

Start Date
End Date
Call
IMI1 - Call 4
Grant agreement number
115369

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
8 975 392
EFPIA in kind
12 360 856
Other
3 938 426
Total Cost
25 274 674

Summary

Most drugs are taken orally, as tablets or capsules for example. However, designing these pharmaceutical products in such a way that the active ingredient is absorbed at an appropriate rate and extent by the gut is far from easy. The ORBITO project set out to enhance our understanding of how orally-administered drugs are taken up from the gastrointestinal tract into the body, and apply this knowledge to create new tests and tools that will better predict the performance of these drugs in patients.

Oral administration is the most common route for medication, which can come in the form of solid tablets, capsules, or chewable tablets, or as drinkable liquids. Solid medications, such as tablets and capsules, deliver the active ingredient to the patient after they dissolve in the gastrointestinal (GI) tract and are then absorbed into the bloodstream.

However, the seemingly simple task of swallowing a pill hides a complex process which is influenced by the drug, the formulation, and GI factors like food and liquid consumption, gastric pH (acidity), and the absorptive capabilities of the digestive tract. To be able to design successful  simulation tools fundamental for the efficient development of new oral pharmaceutical dosage forms, scientists need a thorough knowledge of key aspects of GI physiology and their impact on formulation performance and subsequent drug release behaviour.

The main purpose of the OrBiTo project was to develop and optimise new lab-based and computational tools which could predict the performance of oral drug formulations in patients with greater accuracy than previously available tools.

Aiming to reduce and replace drug absorption studies in animals and humans currently required throughout all phases of drug development, with predictive in vitro and in silico tools, OrBiTo scientists set out to develop a framework for optimal use of tools able to predict the influence of drug form and formulation on oral drug absorption.

Tap or gas

The project’s main achievement is a novel understanding of the oral absorption process based on about 20 mechanistic in vivo studies that resulted in better knowledge of GI fluids and conditions, intestinal wall permeability, and drug concentrations in the GI tract, all of which form the basis for the improvement of in vitro and in silico predictive tools.

By further increasing our understanding of the oral drug absorption process, creating new and refined in vivo predictive tools, validating and standardising key existing tools, as well as developing a guidance for the rational use of an array of different tools, the project’s ultimate goal was to reduce the need for exposing laboratory animals and healthy volunteers to developmental drugs.

An illustrative and interesting discovery of OrBiTo was the impact of sparkling water on the absorption of the painkiller paracetamol when taking a standard tablet. Scientists at KU Leuven investigated the time it takes for paracetamol to reach the small intestine, from where it can be absorbed into the bloodstream. They found that a paracetamol tablet dissolves faster with sparkling water – on average, it took only 10 minutes for the drug to reach the small intestine, compared with half an hour when taken with tap water. Reaching maximum levels of paracetamol in the bloodstream took, on average, 30 minutes with sparkling water, but more than 90 minutes with tap water.

The study proved the important role of the stomach in oral drug absorption, since pressure events in the stomach, which occurred more frequently after intake of sparkling water, can determine the rate of drug dissolution and transfer to the small intestine. It further revealed the challenge of developing drug formulations that can withstand these real-life fluctuations in gastric physiology.

By magnetic resonance imaging (MRI) measurements of gastric volumes, OrBiTo researchers at Greifswald University  discovered that taking oral medicine with food, as commonly recommended, results in a slower rate of drug absorption since it follows the average six-hour long food route to the intestines. More importantly, since water empties from the stomach more rapidly than food, future medicines could be designed to follow the water, and this will result in faster drug absorption.

Other achievements:

  • 15 new or refined in vitro predictive tools;
  • significant standardisation and validation of in vitro predictive tools;
  • decision tools and best practice guidance for the rational use of this array of predictive methods;
  • ring studies with EFPIA partners to determine the inter-laboratory reproducibility of biorelevant dissolution testing;
  • a new database format for the storage of biopharmaceutics and in vivo data populated with historical data from EFPIA;
  • about 170 papers published in leading international pharmaceutics journals;
  • more than 60 examples of the implementation of OrBiTo tools, methods and best practice guides at industrial partners.

By taking a new approach to investigating and validating novel and existing biopharmaceutics tools, and by using active pharmaceutical ingredients, formulations and supporting data from industry partners, OrBiTo scientists were able to capture the full complexity of the GI drug absorption process. They focused on an improved insight into GI physiology and drug absorption, the development of physicochemical and in vitro tools, and  the integration of all data through the application of in silico models of drug absorption.

OrBiTo results will contribute to:

  1. reducing the time and money needed for drug development (a clinical absorption study takes at least six months and a failed late-stage study could lead to delayed drug launch);
  2. lower manufacturing costs through in vivo relevant quality tests, and
  3. the development of better products for patients with improved efficacy/safety properties through improved product designs.

The OrBiTo project brought together more than 150 scientists from 13 industrial and 14 academic, regulatory and technology partners, each contributing with unique expertise and best practice. That provided the opportunity for developing novel and, at the same time, practically useful solutions. The results of the project influenced similar ones outside the EU, such as Cobito, a similar type of consortium started in Japan. The OrBiTo database will be maintained and enriched by a new consortium formed of past members of OrBiTo, and with funding primarily from EFPIA. In addition, two more EU initiatives in the oral biopharmaceutics area – PEARLL and UNGAP, both with the participation of industry and academia, are to follow OrBiTo.

Achievements & News

Drug delivery project ORBITO wins prizes at major conference
November 2015

Scientists from IMI project OrBiTo hit the prize jackpot at the annual meeting of the American Association of Pharmaceutical Scientists (AAPS) in Florida recently. The AAPS meeting is the world’s largest pharmaceutics conference. ORBITO’s prize winners:###

  • Andrés Olivares-Morales of the University of Manchester, UK scooped an AAPS Graduate Student Research Achievement Award in Pharmacokinetics, Pharmacodynamics and Drug Metabolism and Clinical Pharmacology and Translational Research.
  • Philip Jonas Sassene of the University of Copenhagen won an AAPS Lipid-Based Drug Delivery Graduate Student Award.
  • Bart Hens of the University of Leuven won second prize in the AAPS Oral Absorption Focus Group Graduate Student Poster Award.

OrBiTo was highly visible at the conference; the project had a total of seven posters on display, and a symposium featuring speakers from the project was live-streamed via the internet. The goal of OrBiTo is to enhance our understanding of how orally-administered drugs are taken up from the gastrointestinal tract into the body, and apply this knowledge to create new laboratory tests and computer models that will better predict the performance of these drugs in patients.

OrBiTo Open Science Day 1st July – ‘Beyond the BCS based biowaivers’
May 2015

The OrBiTo project plans an Open Science Day with a regulatory focus entitled ‘Beyond the BCS based biowaivers’. The event takes place Wednesday 1st July, 09.00-18.30 in Chilly Mazarin, France, during the three day 2015 OrBiTo annual meeting.### Participants will come from EFPIA partners, universities and SMEs as well as scientists from outside of OrBiTo and regulatory agencies.    
The ORBITO project aims to enhance our understanding of how orally-administered drugs are taken up from the gastrointestinal tract into the body, and apply this knowledge to create new laboratory tests and computer models that will better predict the performance of these drugs in patients. 

More information about the Open Science Day is available through the following sources: 

Participants Show participants on map

EFPIA companies
  • Abbvie Deutschland GMBH & Co Kg, Wiesbaden, Germany
  • Astrazeneca AB, Södertälje, Sweden
  • Bayer Pharma AG, Berlin, Germany
  • Boehringer Ingelheim Internationalgmbh, Ingelheim, Germany
  • Bristol-Myers Squibb Company Corp, Princeton, NJ, United States
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • H. Lundbeck As, Valby, Denmark
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States
  • Novartis Pharma AG, Basel, Switzerland
  • Orion Oyj, Espoo, Finland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Recherche & Developpement, Chilly Mazarin, France
Universities, research organisations, public bodies, non-profit groups
  • Ethniko Kai Kapodistriako Panepistimio Athinon, Athens, Greece
  • Johann Wolfgang Goethe-Universitatfrankfurt Am Main, Frankfurt am Main, Germany
  • Johannes Gutenberg-Universitat Mainz, Mainz, Germany
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • Kobenhavns Universitet, Copenhagen, Denmark
  • Lakemedelsverket, Uppsala, Sweden
  • Nederlandse Organisatie Voor Toegepast Natuurwetenschappelijk Onderzoek Tno, Den Haag, Netherlands
  • The University Of Manchester, Manchester, United Kingdom
  • Universitaet Greifswald, Greifswald, Germany
  • University Of Strathclyde, Glasgow, United Kingdom
  • Uppsala Universitet, Uppsala, Sweden
Small and medium-sized enterprises (SMEs)
  • Certara Uk Limited, London, United Kingdom
  • Simulations Plus, Inc., Lancaster, United States
  • Sirius Analytical Ltd, Forest Row, United Kingdom
Third parties
  • Tno Triskelion BV, Zeist, Netherlands
  • Universitaetsmedizin Der Johannes Gutenberg-Universitaet Mainz, Mainz, Germany
Project coordinator
Bertil Abrahamsson
AstraZeneca AB
Sweden
Managing entity
Hans Lennernäs
Uppsala Universitet